OpenAI partnered with Retro Biosciences to launch an AI model for cellular reprogramming, converting aging cells to younger versions and improving efficiency by 50x using a GPT-4b model.1
Sam Altman invested $180M in Retro Biosciences, supporting this anti-aging science collaboration.1
OpenAI offers enterprise-ready AI solutions for life sciences, accelerating R&D, clinical insights, and workflows.4
OpenAI introduced GPT-Rosalind, a frontier reasoning model for drug discovery and genomics research.6
Tech-pharma alliances are surging, including a16z-Eli Lilly $500M fund, NVIDIA-IQVIA-others for genomics, and Novo Nordisk-Valo Health for obesity and diabetes drugs.1
Sources:
1. https://insider.fitt.co/openai-launches-longevity-model/